
Pharmaceutical R&D calls for unerring and immediate decision-making in view of the global market. The Daiichi Sankyo Group therefore set up GEMRAD (Global Executive Meeting of Research and Development), their top decision-making body, which goes beyond the divisionals and regional frameworks in research and development. An IPT (Integrated Project Team) is organized for each project as a working team which drives development forward by proposing development strategies and policies for those projects to GEMRAD. This organizational framework enables us to make prompt decisions on development projects and push the projects through to completion.
GEMRAD, the top decision-making body in DAIICHI SANKYO’s global R&D, makes management-level decisions from both scientific and business points of view, and effectively manages global R&D activities across both functions and regions.
GEMRAD is comprised of members representing a wide-range of specializedfunctions , i.e. the R&D division, key global sales divisions including Japan, the licensing division, and the divisions responsible for pharmaceutical affairs and product portfolios. Such a broad spectrum of competence allows GEMRAD to make “go/no-go” decisions on development projects based on comprehensive assessments covering all aspects from research to marketing.
Once a go-ahead decision is made on an R&D project by GEMRAD, an IPT (Integrated Project Team) is organized as a working team to promote the project by proposing strategies and policies for that specific project. Specialists in over 20 areas, such as R&D, pharmaceutical affairs, and commercialization from key global markets including Japan, join the IPT as required according to the development stage and progress, and work together to bring the fruits of development onto the global market.
GEMRAD’s role is not limited to “go/non-go” decisions on development projects. For the effective allocation of resources, it also provides a necessary forum to review the progress of individual projects, prioritize projects in the development pipeline and discuss the portfolio management of development items.